{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458270397
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = [[TGF beta 2]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status = Development discontinued
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 285985-06-0
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Lerdelimumab''' ('''CAT-152''', intended trade name '''Trabio''') is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]] developed to reduce scarring after [[Glaucoma surgery|glaucoma drainage surgery]].<ref>{{cite journal|title=Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody|date=1 February 2002|journal=Drugs in R&D|publisher=Adis International|volume=3|issue=2|pages=106–108|url=http://www.ingentaconnect.com/content/adis/rdd/2002/00000003/00000002/art00006|doi=10.2165/00126839-200203020-00006}}</ref> Development was stopped in late 2005 after unsuccessful trial results.<ref>{{cite web|url=http://goliath.ecnext.com/coms2/gi_0199-3895591/CAT-abandons-Trabio-after-second.html |title=CAT abandons Trabio after second clinical trial failure. &#124; Goliath Business News |publisher=Goliath.ecnext.com |date=2005-03-28 |accessdate=2010-05-12}}</ref>

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}
{{TGFβ receptor superfamily modulators}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}